Source-grounded facts extracted from QUEST DIAGNOSTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
QUEST DIAGNOSTICS INC entered into Indenture with The Bank of New York Mellon valued at $500,000,000 aggregate principal amount (effective 2026-05-06).
“On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).”
QUEST DIAGNOSTICS INC reported the quarter ended March 31, 2026 results: revenue $2,895, net income $252, EPS $2.24. Guidance raised.
“implement our first wave of solutions in the fall of 2027. 1 Three Months Ended March 31, 2026 2025 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,895 $ 2,652 9.2 % Diagnostic Information Services revenues $ 2,832 $ 2,589 9.4 % Revenue per requisition (1.3) % Requisition volume 10.9 % Organic requisition volume 10.8 % Operating”
Robert B. Carter was elected as Director at QUEST DIAGNOSTICS INC.
“On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board.”
QUEST DIAGNOSTICS INC reported the quarter ended March 31, 2024 results: revenue $2,366, net income $194, EPS $1.72. Guidance raised.
“adjusted earnings guidance for the full year," Mr. Davis said. Three Months Ended March 31, 2024 2023 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,366 $ 2,331 1.5 % Diagnostic Information Services revenues $ 2,298 $ 2,259 1.7 % Revenue per requisition 0.1 % Requisition volume 1.6 % Organic requisition volume 1.0 % Operating”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.